VCP and ovarian cancer: The synergistic effects were also observed when CB-5083 was substituted with other VCP inhibitors DBeQ and NMS-873 suggesting that mifepristone enhances the cytotoxic effect of VCP inhibitors in ovarian cancer cells (Figure 2B,C and Figure S2B,C).